Cell-Free DNA in Oncology: Gearing up for Clinic

키워드

참고문헌 (77)

1. "C R Seances Soc Biol Fil", 1948, 241~243
2. Jahr S, "DNA fragments in the blood plasma of cancer patients: quantitations and evidence for their origin from apoptotic and necrotic cells", Cancer Res, 61, pp.1659~1665 (2001)
3. Stroun M, "The origin and mechanism of circulating DNA", Ann N Y Acad Sci, 906, pp.161~168 (2000)
4. Stroun M, "About the possible origin and mechanism of circulating DNA", Clinica Chimica Acta, 313, pp.139~142 (2001)[DOI]
5. Papageorgiou EA, "Fetal-specific DNA methylation ratio permits noninvasive prenatal diagnosis of trisomy 21", Nature Medicine, 17, pp.510~513 (2011)[DOI]
6. Lo YD, "Presence of fetal DNA in maternal plasma and serum", Lancet, 350, pp.485~487 (1997)[DOI]
7. Lo YD, "Prenatal diagnosis of fetal RhD status by molecular analysis of maternal plasma", N Engl J Med, 339, pp.1734~1738 (1998)[DOI]
8. Leary RJ, "Development of personalized tumor biomarkers using massively parallel sequencing", Sci Transl Med, 2, pp.20ra14~ (2010)
9. Leary RJ, "Detection of chromosomal alterations in the circulation of cancer patients with whole-genome sequencing", Sci Transl Med, 4, pp.162ra154~ (2012)
10. "Approved Drugs - cobas EGFR Mutation Test v2"[URL]
11. Overman MJ, "Use of research biopsies in clinical trials: are risks and benefits adequately discussed?", J Clin Oncol, 31, pp.17~22 (2013)
12. Murtaza M, "Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA", Nature, 497, pp.108~112 (2013)[DOI]
13. Vanderlaan PA, "Success and failure rates of tumor genotyping techniques in routine pathological samples with non-small-cell lung cancer", Lung Cancer, 84, pp.39~44 (2014)[DOI]
14. Sundaresan TK, "Detection of T790M, the acquired resistance EGFR mutation, by tumor biopsy versus noninvasive blood-based analyses", Clin Cancer Res, 22, pp.1103~1110 (2015)
15. Yanagita M, "A prospective evaluation of circulating tumor cells and cell-free DNA in EGFR-mutant non-small cell lung cancer patients treated with erlotinib on a phase II trial", Clin Cancer Res, 22, pp.6010~6020 (2016)[DOI]
16. Oxnard GR, "Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA", Clin Cancer Res, 20, pp.1698~1705 (2014)[DOI]
17. Newman AM, "An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage", Nat Med, 20, pp.548~554 (2014)[DOI]
18. Kinde I, "Detection and quantification of rare mutations with massively parallel sequencing", Proc Natl Acad Sci U S A, 108, pp.9530~9535 (2011)[DOI]
19. Schmitt MW, "Detection of ultra-rare mutations by next-generation sequencing", Proc Natl Acad Sci U S A, 109, pp.14508~14513 (2012)[DOI]
20. Forshew T, "Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA", Sci Transl Med, 4, pp.136ra68~ (2012)
21. Vogelstein B, "Digital PCR", Proc Natl Acad Sci U S A, 96, pp.9236~9241 (1999)[DOI]
22. Dressman D, "Transforming single DNA molecules into fluorescent magnetic particles for detection and enumeration of genetic variations", Proc Natl Acad Sci U S A, 100, pp.8817~8822 (2003)[DOI]
23. Spindler K-LG, "Quantitative cell-free DNA, KRAS, and BRAF mutations in plasma from patients with metastatic colorectal cancer during treatment with cetuximab and irinotecan", Clin Cancer Res, 18, pp.1177~1185 (2012)[DOI]
24. Sacher AG, "Prospective validation of rapid plasma genotyping for the detection of EGFR and KRAS mutations in advanced lung cancer", JAMA Oncol, 2, pp.1014~1022 (2016)[DOI]
25. "The STRIVE Study: Breast Cancer Screening Cohort"[URL]
26. "Utility of Plasma Circulating Tumor DNA (ctDNA) in Asymptomatic Subjects for the Detection of Neoplastic Disease (H1000)"[URL]
27. "Spanish Lung Liquid vs. Invasive Biopsy Program (SLLIP)"[URL]
28. Moyer VA. Screening for lung cancer: U.S, "Preventive Services Task Force Recommendation Statement", Ann Intern Med, 160, pp.330~338 (2014)
29. U.S. Preventive Services Task Force, "Screening for colorectal cancer: U.S. Preventive Services Task Force Recommendation Statement", Ann Intern Med, 149, pp.627~ (2008)[DOI]
30. U.S. Preventive Services Task Force, "Screening for breast cancer: U.S. Preventive Services Task Force Recommendation Statement", Ann Intern Med, 151, pp.716~ (2009)[DOI]
31. Moyer VA, "Screening for cervical cancer: U.S. Preventive Services Task Force Recommendation Statement", Ann Intern Med, 156, pp.880~ (2012)[DOI]
32. Bettegowda C, "Detection of circulating tumor DNA in early and late stage human malignancies", Sci Transl Med, 16, pp.224ra24~ (2014)
33. "Science I GRAIL's Commitment to Scientific Rigor and Clinical Utility"[URL]
34. "Guardant Health, Pharma Firms to Develop 500-Gene Liquid Biopsy Panel" (2017)[URL]
35. Gormally E, "TP53 and KRAS2 mutations in plasma DNA of healthy subjects and subsequent cancer occurrence: a prospective study", Cancer Res, 66, pp.6871~6876 (2006)[DOI]
36. Zhang BM, "IDH2 mutation in a patient with metastatic colon cancer", N Engl J Med, 376, pp.1991~1992 (2017)[DOI]
37. Abbosh C, "Phylogenetic ctDNA analysis depicts early stage lung cancer evolution", Nature, 545, pp.446~451 (2017)[DOI]
38. Lehmann-Werman R, "Identification of tissue-specific cell death using methylation patterns of circulating DNA", Proc Natl Acad Sci U S A, 113, pp.E1826~E1834 (2016)[DOI]
39. Sun K, "Plasma DNA tissue mapping by genome-wide methylation sequencing for noninvasive prenatal, cancer, and transplantation assessments", Proc Natl Acad Sci U S A, 112, pp.E5503~E5512 (2015)[DOI]
40. Kang S, "CancerLocator: non-invasive cancer diagnosis and tissue-of-origin prediction using methylation profiles of cell-free DNA", Genome Biol, 18, pp.53~ (2017)[DOI]
41. "Alliance Trials - Full Text View -"[URL]
42. Zimmermann FB, "Treatment of recurrent disease in lung cancer", Semin Surg Oncol, 21, pp.122~127 (2003)[DOI]
43. Sadahiro S, "Recurrence patterns after curative resection of colorectal cancer in patients followed for a minimum of ten years", Hepatogastroenterology, 50, pp.1362~1366 (2003)
44. Hourigan CS, "Minimal residual disease in acute myeloid leukaemia", Nat Rev Clin Oncol, 10, pp.460~471 (2013)[DOI]
45. Figueredo A, "Follow-up of patients with curatively resected colorectal cancer: a practice guideline", BMC Cancer, 3, pp.26~ (2003)[DOI]
46. Pita-Fernandez S, "Intensive follow-up strategies improve outcomes in nonmetastatic colorectal cancer patients after curative surgery: a systematic review and meta-analysis", Ann Oncol, 26, pp.644~656 (2014)
47. Chao M, "Caution is required before recommending routine carcinoembryonic antigen and imaging follow-up for patients with early-stage colon cancer", J Clin Oncol, 27, pp.e279~e280 (2009)[DOI]
48. Benson AB, "2000 Update of American Society of Clinical Oncology Colorectal Cancer Surveillance Guidelines", J Clin Oncol, 18, pp.3586~3588 (2000)[DOI]
49. Olsson E, "Serial monitoring of circulating tumor DNA in patients with primary breast cancer for detection of occult metastatic disease", EMBO Mol Med, 7, pp.1034~1047 (2015)[DOI]
50. Garcia-Murillas I, "Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer", Sci Transl Med, 7, pp.302ra133~ (2015)[DOI]
51. Beaver JA, "Detection of cancer DNA in plasma of patients with early-stage breast cancer", Clin Cancer Res, 20, pp.2643~2650 (2014)[DOI]
52. Tie J, "Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer", Sci Transl Med, 8, pp.346ra92~ (2016)[DOI]
53. Reinert T, "Analysis of circulating tumour DNA to monitor disease burden following colorectal cancer surgery", Gut, 65, pp.625~634 (2015)
54. Frattini M, "Quantitative and qualitative characterization of plasma DNA identifies primary and recurrent colorectal cancer", Cancer Lett, 263, pp.170~181 (2008)[DOI]
55. Roschewski M, "Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study", Lancet Oncol, 16, pp.541~549 (2015)[DOI]
56. 김경철, "Circulating cell-free DNA as a promising biomarker in patients with gastric cancer: diagnostic validity and significant reduction of cfDNA after surgical resection", Annals of Surgical Treatment and Research, 86(3), pp.136~142 (2014), 대한외과학회
57. Sausen M, "Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients", Nat Commun, 6, pp.7686~ (2015)[DOI]
58. Diehl F, "Circulating mutant DNA to assess tumor dynamics", Nat Med, 14, pp.985~990 (2007)
59. Jr Diaz LA, "The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers", Nature, 486, pp.537~540 (2012)[DOI]
60. Oxnard GR, "Association between plasma genotyping and outcomes of treatment with osimertinib (AZD9291) in advanced non-small-cell lung cancer", J Clin Oncol, 34, pp.3375~3382 (2016)[DOI]
61. "Blood Sample Monitoring of Patients With EGFR Mutated Lung Cancer"[URL]
62. Schiavon G, "Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer", Sci Transl Med, 7, pp.131ra182~ (2015)
63. Lallous N, "Functional analysis of androgen receptor mutations that confer anti-androgen resistance identified in circulating cell-free DNA from prostate cancer patients", Genome Biol, 17, pp.10~ (2016)[DOI]
64. Azad AA, "Androgen receptor gene aberrations in circulating cell-free DNA: biomarkers of therapeutic resistance in castration-resistant prostate cancer", Clin Cancer Res, 21, pp.2315~2324 (2015)[DOI]
65. Chu D, "ESR1 mutations in circulating plasma tumor DNA from metastatic breast cancer patients", Clin Cancer Res, 22, pp.993~999 (2015)
66. Siravegna G, "Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients", Nat Med, 21, pp.795~801 (2015)[DOI]
67. Morelli MP, "Characterizing the patterns of clonal selection in circulating tumor DNA from patients with colorectal cancer refractory to anti-EGFR treatment", Ann Oncol, 26, pp.731~736 (2015)[DOI]
68. Misale S, "Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer", Nature, 486, pp.532~536 (2012)[DOI]
69. Yu HA, "Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers", Clin Cancer Res, 19, pp.2240~2247 (2013)[DOI]
70. "Press Announcements - FDA approves new pill to treat certain patients with non-small cell lung cancer"[URL]
71. Janne PA, "AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer", N Engl J Med, 372, pp.1689~1699 (2015)[DOI]
72. Sequist LV, "Rociletinib in EGFR-mutated non-small-cell lung cancer", N Engl J Med, 372, pp.1700~1709 (2015)[DOI]
73. Guibert N, "Monitoring KRAS mutations in circulating DNA and tumor cells using digital droplet PCR during treatment of KRAS -mutated lung adenocarcinoma", Lung Cancer, 100, pp.1~4 (2016)[DOI]
74. Guibert N, "Detection and monitoring of the BRAF mutation in circulating tumor cells and circulating tumor DNA in BRAF-mutated lung adenocarcinoma", J Thoracic Oncol, 11, pp.e109~e112 (2016)[DOI]
75. Gray ES, "Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma", Oncotarget, 6, pp.42008~42018 (2015)
76. Bidard FCA-CCA, "Detection rate and prognostic value of circulating tumor cells and circulating tumor DNA in metastatic uveal melanoma", Int J Cancer, 134, pp.1207~1213 (2013)
77. Paweletz CP, "Serial droplet digital PCR (ddPCR) of plasma cell-free DNA (cfDNA) as pharmacodynamic (PD) biomarker in Phase 1 clinical trials for patients (pts) with KRAS mutant non-small cell lung cancer (NSCLC)", American Association for Cancer Research Annual Meeting in 2016. (2016)

관련 논문AI추천